5 Reasons to meet Diaceutics at ASCO | Diaceutics

5 Reasons to meet Diaceutics at ASCO

May 7th, 2019



You have a companion diagnostic (CDx) but . . .

  1. You didn’t . . .
    • start conceiving a strategy to optimize test adoption early in the development stage.
    • establish educational tools to increase physician awareness of your CDx so they know to prescribe your CDx.
    • take precautions to ensure enough tissue sample will be available to run your CDx.
    • investigate the global laboratory network to determine if:
      • lab staff need education on how to properly conduct your CDx test to ensure reliable and consistent results.
      • labs have the technology and platform available to easily and affordably run your CDx.
  2. You didn’t realize that simply introducing a CDx does not guarantee . . .
    • labs will run it.
    • reliable and consistent quality of test results.
    • test results will be available on time for physicians to prescribe the optimal treatment for patients.
    • tests will be affordable for labs to run.
    • tests will be sufficiently reimbursed.
  3. You didn’t realize your diagnostic partner is not well-equipped to help you commercialize the CDx and avoid all the potential hurdles to seamless testing . . . until now.
  4. You didn’t realize the most effective ways to drive uptake of the CDx for your targeted therapy.
  5. You didn’t realize investing the time and money into producing the right CDx for your targeted therapy does not guarantee that labs will run your test. . . ever.

The Hurdles in Diagnostic Testing

Indeed, the pathway to test adoption is rife with hurdles waiting to send your CDx into obscurity, never to be prescribed, run, or reimbursedand never to identify all the patients whose lives could be saved with your targeted treatment. Unfortunately, diagnostic partners are not necessarily aware of these hurdles and certainly do not specialize in avoiding them. But Diaceutics does. That is our business to a CDx “T” as in “test.” How do we do it? Diaceutics has cultivated an expansive, anonymized global “data lake” to deliver patient insights crucial to seamless test adoption. This means more patients treated and increased ROI. 

Come meet the Diaceutics team at ASCO 2019 and find out how you can dive into our global data lake and avoid the many hurdles to test adoption that lead to patient leakage and lost ROI. 

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn